3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
22
Thoracic
5
Gynecologic
5
Gastrointestinal
5
Dermatologic
5
Head & Neck
3
Genitourinary
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
CNS
1
Conditions
Multiple Myeloma
8
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Amyloidosis
1
Interventions
Cyclophosphamide
8
Zoledronic Acid
5
Therapeutics
5
Flow Cytometry
5
pembrolizumab
3
fludarabine
3
Specimen Handling
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Immunologic Techniques
3
Gemcitabine
3
Amplified Fragment Length Polymorphism Analysis
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
liposomal doxorubicin
2
liposomal amphotericin B
2
dabrafenib
2
copanlisib
2
aldesleukin
2
abiraterone
2
Vorinostat
2
Trastuzumab
2
Surveys and Questionnaires
2
Sunitinib
2
Sorafenib
2
Rituximab
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Interleukin-2
×
Plasma cell
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled